Agenus Inc.
AGEN
$1.86
$0.18511.05%
| Weiss Ratings | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.29 | |||
| Price History | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -22.82% | |||
| 30-Day Total Return | -47.46% | |||
| 60-Day Total Return | -39.02% | |||
| 90-Day Total Return | -55.71% | |||
| Year to Date Total Return | -39.81% | |||
| 1-Year Total Return | -84.49% | |||
| 2-Year Total Return | -94.71% | |||
| 3-Year Total Return | -96.38% | |||
| 5-Year Total Return | -95.75% | |||
| 52-Week High % Change | -91.49% | |||
| 52-Week Low % Change | 0.30% | |||
| Price | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.69 | |||
| 52-Week Low Price | $1.67 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | Jun 04, 2024 | |||
| Valuation | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 39.29M | |||
| Enterprise Value | 93.91M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -11.13 | |||
| Earnings Per Share Growth | -31.06% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.23 | |||
| Price/Book (Q) | -0.12 | |||
| Enterprise Value/Revenue (TTM) | 0.59 | |||
| Price | $1.86 | |||
| Enterprise Value/EBITDA (TTM) | -1.10 | |||
| Enterprise Value/EBIT | -0.93 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 21.55M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 674 4400 | |||
| Address | 3 Forbes Road Lexington, MA 02421-7305 | |||
| Website | www.agenusbio.com | |||
| Country | United States | |||
| Year Founded | 1994 | |||
| Profitability | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -62.83% | |||
| Profit Margin | -141.89% | |||
| Management Effectiveness | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -21.95% | |||
| Return on Equity | -- | |||
| Income Statement | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 160.43M | |||
| Total Revenue (TTM) | 160.43M | |||
| Revenue Per Share | $7.44 | |||
| Gross Profit (TTM) | -28.68M | |||
| EBITDA (TTM) | -85.52M | |||
| EBIT (TTM) | -100.80M | |||
| Net Income (TTM) | -227.64M | |||
| Net Income Avl. to Common (TTM) | -227.64M | |||
| Total Revenue Growth (Q YOY) | 3.28% | |||
| Earnings Growth (Q YOY) | -4.16% | |||
| EPS Diluted (TTM) | -11.13 | |||
| EPS Diluted Growth (Q YOY) | 6.36% | |||
| Balance Sheet | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 44.78M | |||
| Cash Per Share (Q) | $2.08 | |||
| Total Current Assets (Q) | 50.15M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -271.80M | |||
| Current Ratio (Q) | 0.185 | |||
| Book Value Per Share (Q) | -$13.48 | |||
| Total Assets (Q) | 238.48M | |||
| Total Current Liabilities (Q) | 270.64M | |||
| Total Debt (Q) | 78.87M | |||
| Total Liabilities (Q) | 510.29M | |||
| Total Common Equity (Q) | -292.34M | |||
| Cash Flow | AGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 2.87M | |||
| Cash from Financing (TTM) | 105.79M | |||
| Net Change in Cash (TTM) | -61.56M | |||
| Levered Free Cash Flow (TTM) | -32.39M | |||
| Cash from Operations (TTM) | -170.07M | |||
